Abstract
Genome complexity and diversity can be due to Alternative Splicing (AS), a process by which one gene can generate multiple mRNA isoforms and then several proteins. This is part of a normal process of variation on an individual, and when it is disrupted or modified, may trigger disease. To date, there are many pathologies described due to the effects of altered splicing isoforms, and effort is focused on the description of new ones. The design of drug target has to consider splicing, as in many occasions, a drug might have effect on different isoforms, instead of on the particular one implicated in the pathology. Interestingly, the strategies used to alter splicing can be used to modify a form towards the canonical one, or towards an aberrant one, when the latter one has a beneficial effect on the individual. Here we describe differential splicing, diseases produced by alterations on the mRNA isoforms, and drugs or methods used to restore these alterations.
Keywords: Alternative splicing, miRNA, siRNA, mRNA isoform, antisense oligonucleotide, SSOs
Infectious Disorders - Drug Targets
Title: Differential Splicing, Disease and Drug Targets
Volume: 8 Issue: 4
Author(s): O. Villate, A. Rastrojo, R. Lopez-Diez, F. Hernandez-Torres and B. Aguado
Affiliation:
Keywords: Alternative splicing, miRNA, siRNA, mRNA isoform, antisense oligonucleotide, SSOs
Abstract: Genome complexity and diversity can be due to Alternative Splicing (AS), a process by which one gene can generate multiple mRNA isoforms and then several proteins. This is part of a normal process of variation on an individual, and when it is disrupted or modified, may trigger disease. To date, there are many pathologies described due to the effects of altered splicing isoforms, and effort is focused on the description of new ones. The design of drug target has to consider splicing, as in many occasions, a drug might have effect on different isoforms, instead of on the particular one implicated in the pathology. Interestingly, the strategies used to alter splicing can be used to modify a form towards the canonical one, or towards an aberrant one, when the latter one has a beneficial effect on the individual. Here we describe differential splicing, diseases produced by alterations on the mRNA isoforms, and drugs or methods used to restore these alterations.
Export Options
About this article
Cite this article as:
Villate O., Rastrojo A., Lopez-Diez R., Hernandez-Torres F. and Aguado B., Differential Splicing, Disease and Drug Targets, Infectious Disorders - Drug Targets 2008; 8 (4) . https://dx.doi.org/10.2174/187152608786734188
DOI https://dx.doi.org/10.2174/187152608786734188 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Tumor Ubiquitin-Proteasome Pathway with Polyphenols for Chemosensitization
Anti-Cancer Agents in Medicinal Chemistry Targeted Cancer Therapy: The Next Generation of Cancer Treatment
Current Drug Discovery Technologies Roles of Medicinal Plants and Constituents in Gynecological Cancer Therapy: Current Literature and Future Directions
Current Topics in Medicinal Chemistry Dynamics of Virus-Host Interplay in HIV-1 Replication
Current HIV Research Clinical Application of Lentiviral Vectors – Concepts and Practice
Current Gene Therapy Novel Drug Delivery Systems for Sustained and Targeted Delivery of Anti-Cancer Drugs: Current Status and Future Prospects
Current Drug Delivery (Iso)Flav(an)ones, Chalcones, Catechins, and Theaflavins as Anticarcinogens: Mechanisms, Anti-Multidrug Resistance and QSAR Studies
Current Medicinal Chemistry Recent Advances and Approaches in Targeting Apoptosis Signaling Pathways for Anti-Cancer Therapeutics
Current Cancer Therapy Reviews Targeted Tumor Diagnosis and Therapy with Peptide Hormones as Radiopharmaceuticals
Anti-Cancer Agents in Medicinal Chemistry Complications of Muscle Hematomas in Hemophilia
Cardiovascular & Hematological Disorders-Drug Targets Molecular Signatures of Biomarkers in Cancer Development, Diagn osis, and its Prognostic Accuracy
Current Biomarkers (Discontinued) Recent Advances in Molecular Biology of Parasitic Viruses
Infectious Disorders - Drug Targets Development of PET Probes for Cancer Imaging
Current Topics in Medicinal Chemistry Electroporation in DNA Vaccination Protocols Against Cancer
Current Drug Metabolism Markov-Randic Indices for QSPR Re-Evaluation of Metabolic, Parasite- Host, Fasciolosis Spreading, Brain Cortex and Legal-Social Complex Networks
Current Bioinformatics Stationary Wavelet Transform and AdaBoost with SVM Based Pathological Brain Detection in MRI Scanning
CNS & Neurological Disorders - Drug Targets Current Therapeutic Leads for the Treatment of Melanoma: Targeted Immunotherapy in the Post-genomic Era
Current Molecular Pharmacology Immunopathology of Type 1 Diabetes and Immunomodulatory Effects of Stem Cells: A Narrative Review of the Literature
Endocrine, Metabolic & Immune Disorders - Drug Targets Chemosensitization by Antisense Oligonucleotides Targeting MDM2
Current Cancer Drug Targets Clinical Development of mTOR Inhibitors: A Focus on Lymphoma
Reviews on Recent Clinical Trials